Literature DB >> 11217070

Effect of retinoids on growth inhibition of two canine melanoma cell lines.

E Ohashi1, S H Hong, T Takahashi, T Nakagawa, M Mochizuki, R Nishimura, N Sasak.   

Abstract

Two new canine melanoma cell lines (CMM1 and CMM2) were established from the patients with oral malignant melanomas. Histopathological type of both CMM1 and CMM2 was a mixed cell type consisted of spindle-shaped cells, polygonal cells, and oval cells. Doubling time of CMMI and CMM2 were 18.4 +/- 1.96 hr and 21.0 +/- 0.73 hr, respectively. The effect of two kinds of retinoids (all-trans retinoic acid and 9-cis retinoic acid) on the proliferation of these cells were examined by morphological changes, proliferation assay and apoptosis assay. However, the retinoids did not suppress growth rate of these cells. This result suggests that retinoids used in this study did not induce differentiation, apoptosis, and growth inhibition of the canine melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11217070     DOI: 10.1292/jvms.63.83

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  8 in total

1.  Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.

Authors:  Naoya Maekawa; Satoru Konnai; Yumie Asano; Yamato Sajiki; Tatsuya Deguchi; Tomohiro Okagawa; Kei Watari; Hiroto Takeuchi; Satoshi Takagi; Kenji Hosoya; Sangho Kim; Hiroshi Ohta; Yukinari Kato; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

2.  In vitro chemosensitivity of canine mast cell tumors grades II and III to all-trans-retinoic acid (ATRA).

Authors:  K C Pinello; M Nagamine; T C Silva; P Matsuzaki; H V Caetano; L N Torres; H Fukumasu; J L Avanzo; J M Matera; M L Z Dagli
Journal:  Vet Res Commun       Date:  2009-01-14       Impact factor: 2.459

3.  Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.

Authors:  Mona Uchida; Kohei Saeki; Shingo Maeda; Satoshi Tamahara; Tomohiro Yonezawa; Naoaki Matsuki
Journal:  J Vet Med Sci       Date:  2016-05-30       Impact factor: 1.267

4.  Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers.

Authors:  Hiroto Takeuchi; Satoru Konnai; Naoya Maekawa; Erina Minato; Yoshiki Ichikawa; Atsushi Kobayashi; Tomohiro Okagawa; Shiro Murata; Kazuhiko Ohashi
Journal:  Front Vet Sci       Date:  2020-06-11

5.  PDPN Is Expressed in Various Types of Canine Tumors and Its Silencing Induces Apoptosis and Cell Cycle Arrest in Canine Malignant Melanoma.

Authors:  Masahiro Shinada; Daiki Kato; Satoshi Kamoto; Sho Yoshimoto; Masaya Tsuboi; Ryohei Yoshitake; Shotaro Eto; Namiko Ikeda; Kohei Saeki; Yuko Hashimoto; Yosuke Takahashi; James Chambers; Kazuyuki Uchida; Mika K Kaneko; Naoki Fujita; Ryohei Nishimura; Yukinari Kato; Takayuki Nakagawa
Journal:  Cells       Date:  2020-05-05       Impact factor: 6.600

6.  Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma.

Authors:  Satoshi Kamoto; Masahiro Shinada; Daiki Kato; Sho Yoshimoto; Namiko Ikeda; Masaya Tsuboi; Ryohei Yoshitake; Shotaro Eto; Yuko Hashimoto; Yosuke Takahashi; James Chambers; Kazuyuki Uchida; Mika K Kaneko; Naoki Fujita; Ryohei Nishimura; Yukinari Kato; Takayuki Nakagawa
Journal:  Cells       Date:  2020-11-23       Impact factor: 6.600

7.  The impact of damage-associated molecules released from canine tumor cells on gene expression in macrophages.

Authors:  Shotaro Eto; Hideyuki Yanai; Sho Hangai; Daiki Kato; Ryohei Nishimura; Takayuki Nakagawa
Journal:  Sci Rep       Date:  2021-04-19       Impact factor: 4.379

8.  Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.

Authors:  Naoya Maekawa; Satoru Konnai; Ryoyo Ikebuchi; Tomohiro Okagawa; Mami Adachi; Satoshi Takagi; Yumiko Kagawa; Chie Nakajima; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.